- Home
- KZIA vs DHF Comparison
KZIA vs DHF Comparison
Compare KZIA & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KZIA | DHF |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 185.7M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZIA | DHF |
|---|---|---|
| Price | $10.80 | $2.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | 292.8K | ★ 451.1K |
| Earning Date | 12-26-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,199,108.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $2.06 |
| 52 Week High | $17.40 | $2.39 |
Technical Indicators
Market Signals| Indicator | KZIA | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 39.92 |
| Support Level | $8.91 | $2.49 |
| Resistance Level | $12.20 | $2.55 |
| Average True Range (ATR) | 2.36 | 0.02 |
| MACD | -0.45 | -0.00 |
| Stochastic Oscillator | 32.10 | 22.22 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.